


**CORRECTION**



# Correction to: Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study

Stephen Whebell<sup>1,6\*</sup> , Joe Zhang<sup>2,3</sup>, Rebecca Lewis<sup>1</sup>, Michael Berry<sup>2</sup>, Stephane Ledot<sup>4</sup>, Andrew Retter<sup>1</sup> and Luigi Camporota<sup>1,5</sup>

© 2022 Springer-Verlag GmbH Germany, part of Springer Nature

## Correction to: *Intensive Care Med*

<https://doi.org/10.1007/s00134-022-06645-w>

Unfortunately, the last three lines of Table 1 are incorrect. Please find the correct Table 1 below. The authors apologize for the mistake.

---

\*Correspondence: [swhebell@gmail.com](mailto:swhebell@gmail.com)

<sup>6</sup> Department of Adult Critical Care, St Thomas' Hospital, London SE1 7EH, UK

Full author information is available at the end of the article

The original article can be found online at <https://doi.org/10.1007/s00134-022-06645-w>.

**Table 1 Characteristics, decision and outcomes of COVID-19 patients referred for ECMO**

	All referrals (n = 1383)	Included for matching (n = 933)	'Perceived futility' (n = 430)	p value
<b>Demographics</b>				
Age	53 [45, 60]	51 [43, 58]	58 [52, 63]	< 0.001
Male sex	941 (69)	641 (68.7)	300 (69.8)	0.74
Body mass index (kg/m <sup>2</sup> )	31.01 [27.02, 35.46]	31.35 [27.34, 35.64]	29.88 [26.31, 34.64]	0.002
Clinical Frailty Scale	2 [2, 2]	2 [2, 2]	2 [2, 2]	< 0.001
Immunocompromised	82 (6)	40 (4.3)	42 (9.8)	< 0.001
<b>Pre-referral admission characteristics</b>				
Hospital duration prior to IMV (days)	5 [2, 8]	4.5 [2, 7.92]	6.52 [3, 9.38]	< 0.001
IMV duration <sup>a</sup> (days)	3.15 [1, 6]	3 [1, 6]	4 [2, 9]	< 0.001
Cardiac arrest	43 (3.2)	24 (2.6)	19 (4.4)	0.1
<b>Therapeutic interventions</b>				
Non-invasive ventilation <sup>b</sup> prior to IMV	921 (67.6)	612 (65.6)	309 (71.9)	0.025
Corticosteroids	910 (66.8)	606 (65)	304 (70.7)	0.042
Interleukin-6 inhibitor	117 (8.6)	77 (8.3)	40 (9.3)	0.59
Neuromuscular blockade	1178 (86.4)	803 (86.1)	375 (87.2)	0.626
Prone position trial	1054 (77.3)	712 (76.3)	342 (79.5)	0.211
Inhaled nitric oxide use	168 (12.3)	98 (10.5)	70 (16.3)	0.003
Chest drain(s) for pneumothorax	83 (6.1)	55 (5.9)	28 (6.5)	0.749
Renal replacement therapy	135 (9.9)	63 (6.8)	72 (16.7)	< 0.001
Noradrenaline dose (mcg/kg)	0.04 [0, 0.12]	0.03 [0, 0.1]	0.06 [0.01, 0.19]	< 0.001
Anticoagulation				< 0.001
Contraindicated	11 (0.8)	7 (0.8)	4 (0.9)	
Prophylactic	883 (64.8)	647 (69.3)	236 (54.9)	
Therapeutic	469 (34.4)	279 (29.9)	190 (44.2)	
<b>Respiratory parameters at time of referral</b>				
P/F ratio (mmHg)	78.33 [64.7, 97.78]	80 [67.28, 100.5]	73.93 [61.5, 91.67]	< 0.001
Static compliance (ml/cmH <sub>2</sub> O)	28.87 [20.89, 35.71]	30 [22, 37]	26.4 [19.44, 33.72]	< 0.001
Vt/PBW (mL/kg)	6.7 [5.98, 7.87]	6.74 [6.06, 7.99]	6.55 [5.78, 7.61]	0.001
Driving pressure (cmH <sub>2</sub> O)	16 [13, 20]	15.7 [13, 19]	17 [14, 22]	< 0.001
Plateau pressure (cmH <sub>2</sub> O)	29 [25, 31]	29 [25, 31]	29 [25, 32]	0.065
Positive end expiratory pressure (cmH <sub>2</sub> O)	12 [10, 14]	12 [10, 14]	12 [10, 14]	0.218
Minute ventilation (L/min)	9.84 [8, 11.52]	9.88 [8.04, 11.5]	9.65 [7.92, 11.63]	0.715
<b>Arterial blood gas parameters at time of referral</b>				
pH	7.31 [7.24, 7.38]	7.32 [7.25, 7.39]	7.29 [7.20, 7.36]	< 0.001
pCO <sub>2</sub> (mmHg)	59.62 [50.25, 71.03]	58.12 [49.2, 68.55]	63.9 [53.25, 77.25]	< 0.001
Bicarbonate (mmol/L)	27.02 [24, 31.45]	26.98 [24.08, 30.75]	27.6 [24, 32.6]	0.066
Base excess (mmol/L)	3.73 [1.8, 7.8]	3.6 [1.8, 7.4]	4.05 [1.8, 8.4]	0.219
Lactate (mmol/L)	1.3 [1, 1.8]	1.3 [1, 1.7]	1.4 [1, 1.8]	0.111
<b>Laboratory parameters at time of referral</b>				
Haemoglobin (g/L)	113.55 [98, 126]	115 [101, 127]	108.5 [92, 124]	< 0.001
White cell count (10 <sup>9</sup> /L)	12.04 [9.31, 15.55]	11.86 [9.2, 15]	12.91 [9.8, 16.88]	0.001
Platelets (10 <sup>9</sup> /L)	272.1 [229, 319.91]	278.17 [235, 325]	263.78 [218.14, 307.27]	< 0.001
Creatinine (μmol/L)	73 [56, 99.63]	71 [55, 93]	79 [59.25, 117.5]	< 0.001
C reactive protein (mg/L)	165.63 [76.5, 270.1]	170 [80, 274]	148.47 [68, 260]	0.1
<b>Severity and risk scores</b>				
RESP score	4 [2.13, 5]	5 [3, 5]	3 [1, 4]	< 0.001
SOFA score	5.9 [4, 8]	5 [4, 7]	7 [4, 8]	< 0.001
<b>Referral outcomes</b>				
Meets NHS criteria	608 (46.8)	463 (52.7)	145 (34.5)	< 0.001

**Table 1 (continued)**

	All referrals ( <i>n</i> = 1383)	Included for matching ( <i>n</i> = 933)	'Perceived futility' ( <i>n</i> = 430)	<i>p</i> value
Perceived futility	430 (31.5)	0 (0)	430 (100)	< 0.001
Treated with ECMO	243 (17.8)	243 (26)	0 (0)	< 0.001
Died	717 (52.6)	403 (43.2)	314 (73)	< 0.001

Values are expressed as median value [95% CI] or as *n* (%); *p* values for comparison statistics computed for 'perceived futility' vs other referral decision only

*IMV* invasive mechanical ventilation, *P/F ratio* partial pressure of arterial oxygen to fraction of inspired oxygen ratio, *Vt* tidal volume, *PBW* predicted body weight, *RESP* respiratory ECMO survival prediction, *SOFA* sequential organ failure assessment, *NHS* national health service

<sup>a</sup> *IMV* duration includes all days of *IMV*, regardless of intensity

<sup>b</sup> *NIV* use does not include high flow oxygen therapy

#### Author details

<sup>1</sup> Department of Adult Critical Care, Guy's and St Thomas' NHS Foundation Trust, London, UK. <sup>2</sup> Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. <sup>3</sup> Institute of Global Health Innovation, Imperial College London, London, UK. <sup>4</sup> Department of Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, London, UK. <sup>5</sup> Division of Asthma, Allergy and Lung Biology, King's College London, London, UK. <sup>6</sup> Department of Adult Critical Care, St Thomas' Hospital, London SE1 7EH, UK.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published: 18 March 2022